Evidence map›Paper›PMID 41667884›Full record

ArticleThe AAPS journal2026

Utility of Modeling and Simulations in Drug Development: Contrasting Japan, US and UK Descriptions of PBPK Modeling from Package Inserts.

Shinji Kudo, Hirokazu Wakuda, Ichiro Oikawa, Ai Sekiguchi, Yusuke Nakamura, Taisuke Hojo, Hiromitsu Imai, Megumi Kai, Naoto Uemura

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shinji KudoDepartment of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan.ORCID 0009-0004-8670-5219
Hirokazu WakudaClinical Pharmacology Center, Oita University Hospital, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan. wakuda@oita-u.ac.jp.ORCID 0000-0002-5717-8251
Ichiro OikawaGeneral Clinical Research Center, Oita University Hospital, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan.ORCID 0000-0001-8628-2843
Ai SekiguchiDepartment of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan.ORCID 0000-0001-8118-6043
Yusuke NakamuraDepartment of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan.ORCID 0009-0002-7112-2518
Taisuke HojoDepartment of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan.ORCID 0009-0005-5599-0042
Hiromitsu ImaiDepartment of Medical Ethics, Faculty of Medicine, Oita University, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan.ORCID 0000-0001-7805-1180
Megumi KaiDepartment of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan.ORCID 0009-0000-0024-7212
Naoto UemuraDepartment of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idai Gaoka, Hasama-Cho, Yufu City, Oita, 879-5593, Japan.ORCID 0000-0002-3722-8979

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Physiologically based pharmacokinetic (PBPK) modeling is a mathematical method for predicting drug pharmacokinetics based on individual physiological information, and its usefulness has been attracting attention in recent years. This study aimed to investigate and compare the extent to which PBPK models are utilized in drug package inserts in Japan, the United States, and Europe. We searched the official websites of the PMDA, FDA, and EMA to examine the number and content of drugs that mention the use of PBPK modeling as of 2024. Furthermore, we compared the consistency and detail of the descriptions between Japan, the United States, and Europe. As a result, 38 drugs in Japan listed PBPK modeling, many of which were related to drug-drug interactions. Compared with Europe, there were no complete matches and only seven partial matches, while compared with the United States, there were two complete matches and 24 partial matches. A comparison of the details of the 24 partial matches revealed a tendency for Japanese package inserts to be more detailed. PBPK model analysis has become increasingly important in recent drug development, and Japan in particular has a tendency to provide more detailed information on package inserts. This study suggests the potential for further utilization of PBPK models in the field of clinical pharmacology.

Indexed as

Drug DevelopmentDrug LabelingModels, BiologicalPharmacokineticsComputer SimulationDrug InteractionsHumansJapanPharmaceutical PreparationsUnited KingdomUnited StatesPharmaceutical Preparationsdrug Developmentmodeling and Simulation (M&S)package Insertsphysiologically-based Pharmacokinetic (PBPK)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.